About the Company
Celsion is committed to the development of efficient, effective, and targeted therapies for the treatment of cancer and other difficult-to-treat diseases, with the goal of improving patient outcomes in underserved indications. Our extensive, complementary clinical pipeline, stretching from discovery to Phase III, is driven by innovative platform technologies in the areas of chemotherapy, immunotherapy, and DNA- and RNA-based therapy.
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary...
Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary...
Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium
LAWRENCEVILLE, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced that Khursheed Anwer, Ph.D., Celsion’s executive vice president and chief science officer, presented two posters on February 23, 2017 at the American Society of Clinical Oncology (ASCO)...
NEW YORK, NY / ACCESSWIRE / February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Celsion Corp. (CLSN) today, in light of recent...